Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Inclusion Criteria:

- Insulin naïve subject (allowed are: previous short term insulin treatment up to 14
days; Treatment during hospitalisation or during gestational diabetes is allowed for
periods longer than 14 days)

- Current treatment: metformin monotherapy or metformin in any combination with an
insulin secretagogue (sulfonylurea or glinide), DPP-4 inhibitor,
alpha-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months
prior to visit 1 with the minimum doses stated: -Metformin: alone or in combination
(including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000
mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the daily
maximal dose according to local labelling -DPP-4 inhibitor: minimum half of the daily
maximal dose according to local labelling - alpha-glucosidase-inhibitors (acarbose):
minimum half of the daily maximal dose or maximum tolerated dose

- HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

- Body Mass Index (BMI) maximum 45.0 kg/m^2

- Type 2 diabetes (diagnosed clinically) for at least 6 months

- Ability and willingness to adhere to the protocol including performance of self
monitored plasma glucose (SMPG) profiles according to the protocol

Exclusion Criteria:

- Use within the last 3 months prior to Visit 1 of: thiazoledinediones (TZDs),
exenatide or liraglutide

- Cardiovascular disease, within the last 6 months prior to Visit 1, defined as:
stroke; decompensated heart failure New York Heart Association (NYHA) class III or
IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass
graft or angioplasty

- Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

- Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
contraceptive measures according to local requirements [for UK: adequate
contraceptive measures are defined as established use of oral, injected or implanted
hormonal methods of contraception, sterilisation, intrauterine device or intrauterine
system, or consistent use of barrier methods]

- Cancer and medical history of cancer hereof (except basal cell skin cancer or
squamous cell skin cancer)